UK’s Colorectal Cancer market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX.X% during the forecast period.
Colorectal cancer incidence in the UK and other high-income countries has been increasing rapidly among young adults. This is the first analysis of colorectal cancer incidence trends by sub-site and socioeconomic deprivation in young adults in a European country. There are around 42,300 new bowel cancer cases in the UK every year, that is more than 110 every day. Bowel cancer incidence rates in England in females are similar in the most deprived quintile compared with the least, and in males are 9% higher in the most deprived quintile compared with the least.
Colorectal cancer is one of the most common cancers in the UK, so there is lots of evidence looking at what can cause it to develop. Previous research has shown that regardless of age, overweight and obesity, a diet low in fibre and high in processed and red meat, drinking alcohol and not being active can all increase the risk of bowel cancer. The rise in pipeline colorectal cancer screening tests is one of the major drivers for the colorectal cancer market. In UK, screening colonoscopy with full insurance reimbursement is available for individuals aged 55 and above, and/or for persons with well-known risk factors for CRC.
Furthermore, the companies are focusing more on the development of new diagnostic tests that will help in the accurate detection of colorectal cancer which will further drive the market in future.